-

AmboVent Shares Its Open-source, Build-it-yourself Breathing Machine to Help Win the Race Against the Global Ventilator Shortage

Israeli nonprofit launches a crowdfunding campaign to enable mass production of its ventilators worldwide

NEW YORK & TEL AVIV--(BUSINESS WIRE)--AmboVent, an Israeli nonprofit that developed a resuscitator device powered by a robotic arm and sophisticated computer system, announced today a crowdfunding campaign to allow its invention to be built anytime, anywhere.

The device was developed in a matter of 10 days by a team of entrepreneurs and organizations led by Dr. David Alkahar and Dr. Eitan Eliram, as part of the global Coronavirus pandemic response. The project was shared via Github, an open-source platform, which allows the entire design to be accessible to developers and engineers around the globe. The AmboVent machine is expected to cost less than $1,000 when mass-produced – a fraction of the cost of a full-featured resuscitator device. The invention was made possible in part by support from tech companies such as Lemonade, the AI-powered insurance company, whose team members helped get the project off the ground.

“The shortage and expense of life-saving ventilators have been a major concern since the pandemic began, and is an especially acute worry as Covid-19 accelerates in the developing world,” said Daniel Schreiber, Lemonade CEO and cofounder. “As an open-source, technology-driven effort to save lives, AmboVent was one of the initiatives our team was keen to help out with.”

Currently, the project team is working in collaboration with over 100 development teams across 30 countries.

Dr. Eitan Eliram, AmboVent Director of Global Partnerships, added: “Our goal is to support the development and local mass production capabilities of ventilators in many countries. We are excited to offer our open-source design and technical support to all people, countries, and governments. This is a time for humanity to come together.”

AmboVent launched a joint crowdfunding campaign to raise funds, enabling the nonprofit the opportunity to directly give the hope of life to many Covid-19 patients in countries where other breathing support devices are not currently available.

Support the effort to win the race against COVID-19! Donate here - https://www.causematch.com/en/projects/ambovent-en/

For partnership opportunities, contact Dr. Eitan Eliram: Email: dreliram@gmail.com Phone: +972 50 656 3762

Contacts

Lisa Horton
lisa@astrskpr.com
845-467-3286

AmboVent


Release Versions

Contacts

Lisa Horton
lisa@astrskpr.com
845-467-3286

More News From AmboVent

Lemonade Car Launches in Texas

NEW YORK--(BUSINESS WIRE)--Lemonade (NYSE: LMND), the digital insurance company powered by AI and social impact, today announced the launch of Lemonade Car in Texas, making it the latest state to offer the company’s telematics-enabled car insurance and also the full suite of Lemonade insurance products. “Texas presents an incredible opportunity for us not only because of its sheer market size, but also because it’s the latest state to feature every one of Lemonade’s products, continuing our str...

Lemonade To Hold Investor Day On Tuesday, November 15

NEW YORK--(BUSINESS WIRE)--Lemonade, Inc. (NYSE: LMND) will hold an in-person Investor Day on Tuesday, November 15, 2022 in New York City. A live webcast of the event will be available on the Lemonade Investor Relations website, investor.lemonade.com. Following the event, a replay will also be made available at investor.lemonade.com. To register for the online event, please use this link. Please note that in-person attendance is by invitation only and advance registration is required. If you ar...

Lemonade Announces Third Quarter 2022 Financial Results

NEW YORK--(BUSINESS WIRE)--Lemonade, Inc. (NYSE: LMND) has released its third quarter 2022 financial results by posting them to its website. Please view the Q3 2022 financial results in the Letter to Shareholders on the company’s investor relations website. On Wednesday, November 9, 2022, Lemonade will host a conference call at 8:00 a.m. Eastern time (5:00 a.m. Pacific time) to discuss the results. To register for this conference call (Conference ID 10165840), please use this link. Registrants...
Back to Newsroom